Stifel Nicolaus analyst Rick Wise maintained a Buy rating on LivaNova (LIVN – Research Report) today and set a price target of $65.00. The company’s shares closed yesterday at $46.86.
Wise covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Baxter International, and Intuitive Surgical. According to TipRanks, Wise has an average return of 4.1% and a 55.78% success rate on recommended stocks.
Currently, the analyst consensus on LivaNova is a Moderate Buy with an average price target of $59.67, representing a 27.34% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $68.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $59.86 and a one-year low of $40.26. Currently, LivaNova has an average volume of 400.2K.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LIVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LivaNova (LIVN) Company Description:
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular, Neuromodulation, and Others. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The Other segment consists of company’s shared service expenses for finance, legal, human resources, information technology, and new ventures. Its products include VNS therapy system. oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, and cannulae. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.
Read More on LIVN:
